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Abstract
Ovarian germ cell tumors (OGCTs) comprise 20–25% of all ovarian cancers arising from 
germ cells of ovary. Mature teratoma (dermoid) is the only benign and commonest germ 
cell tumor. Only 3–5% germ cell tumors are malignant, dysgerminomas being the most 
common. These tumors occur in adolescents and reproductive age group. Hence, its asso-
ciation with pregnancy is not uncommon. They can be reliably diagnosed with ultra-
sound imaging. Raised levels of tumor markers in pregnancy should be interpreted with 
caution. Cystectomy can be done for benign germ cell tumors. However, fertility sparing 
surgery with surgical staging with or without adjunctive therapy is recommended for 
malignant germ cell tumors (MOGTs). Surgery is safe in the second trimester of preg-
nancy. MOGTs are quite sensitive to chemo and radiotherapy. Three to four courses of 
chemotherapy with bleomycin, etoposide, and platinum is recommended. Prognosis of 
these germ cell tumors is excellent.
Keywords: germ cell, germ cell tumors, dermoid cyst in pregnancy, dysgerminoma in 
pregnancy, immature teratoma, BEP therapy
1. Introduction
Germ cells are the cells in the body that develop into sperms and eggs or oogonia, the 
gametes. The precursors of germ cells are termed primordial germ cells (PGCs). Like all 
other somatic cells, the primordial germ cells are diploid. They are present in yolk sac dur-
ing early embryonic life, and migrate from the yolk sac to its destination, gonadal ridges 
in the developing gonads. These PGCs proliferate and finally differentiate into oogonia in 
females. The development and differentiation of PGCs is crucial for assuring normal fertil-
ity and the genomic transmission to the next  generation [1]. These germ cells are mainly 
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found in the gonads. But, they can sometimes be left behind in other parts of the body dur-
ing intrauterine development of the individual (extragonadal germ cells).
2. Germ cell tumors
Germ cell tumors (GCTs) are derived from primitive germ cells. More than 90% of GCTs 
develop in the gonads; ovary or testicle, the remainder is extragonadal, and distributed along 
the midline of the body, i.e., mediastinum, CNS, retroperitoneum, and sacrococcygeal region 
[2]. Deregulation of imprinted genes can be associated with tumorigenesis and altered cell 
differentiation capacity. Ovarian germ cell tumors may be distinguished by their line of dif-
ferentiation. These tumors can arise from:
1. Primitive totipotent germ cells, i.e., dysgerminoma
2. Primordial germ cells which differentiate into embryonal or extraembryonal cells.
a. Embryonal cells from which mature and immature teratoma can arise.
b. Extraembryonal cells i.e., trophoblast and yolk sac from which choriocarcinoma and 
endodermal sinus tumor can arise respectively.
Ovarian germ cell tumors differ in clinical presentation, histology and biology, and include 
both benign (predominantly) and malignant subtypes. They constitute about 20–25% of all 
ovarian neoplasms. Only 5% of germ cell tumors are malignant, with most (95%) being benign 
mature cystic teratomas. Ovarian malignant germ cell tumors (OMGCTs) include, in order 
of frequency, dysgerminomas, immature teratomas, yolk sac tumors, and mixed germ cell 
tumors. Other less common OMGCTs include embryonal carcinomas, choriocarcinomas, and 
malignant struma ovarii tumors. OMGCTs constitute about 5% of all malignant ovarian neo-
plasms [3].
A review of the Surveillance, Epidemiology, and End Results (SEER) data taken between 
1973 and 2002 reported an incidence of OMGCTs of 3.4/1,000,000 women in the USA [4] and a 
survey of GCTs in England between 1979 and 2003 [4] reported an incidence of 2.34/1,000,000 
women [5]. Data from other countries have reported higher incidence of 5% [3].
The incidence of OGCT is not variable throughout the world. In contrast to epithelial ovarian 
cancers, there appears to be no racial predisposition; however, incidence of OMGCTs in the Saudi 
Arabian population (13.8%) was reported approximately three times the incidence of Western 
populations (5%) and roughly matched the incidence of Asian and African populations (15%) [6].
OMGCTs predominantly occur in young women, but can occur in various other age groups, 
with the highest incidence in 15–19 years age. The incidence of OGCT increases from the age 
8–9 years and peaks at 18 years (20 per million). The mean age of presentation is 19 years. In 
the first two decades of life, more than 60% of ovarian tumors are of germ cell origin, and one-
third of these are malignant. The incidence of OGCT is much lower than testicular tumors; 
10.4 per million in females compared to 44.5 per million in males at [7].
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3. WHO classification (three categories)
a. Primitive gem cell tumors:
i. Dysgerminomas
ii. Nondysgerminomas (yolk sac tumors, embryonal carcinoma, polyembryoma, nonges-
tational carcinoma, and mixed tumors)
b. Biphasic and triphasic germ cell tumors—teratomas
c. Monodermal teratoma and somatic type tumors associated with dermoid cyst
4. Etiology of germ cell tumors
Etiological factors for GCT are ill-understood, apart from an increased incidence associated 
with dysgenetic gonads. Five percent of patients with dysgerminomas are associated with 
abnormalities involving the entire or part of the Y chromosome, 46 XY (testicular feminisa-
tion), gonadal dysgenesis and mixed gonadal dysgenesis (45 X, 46 XY). However, 95% of 
females with dysgerminomas are cytogenetically normal [7].
Chromosome 12p abnormalities are frequent in dysgerminoma of the ovary. FISH analysis for 
chromosome 12p abnormalities may be a used for confirming the diagnosis of dysgerminoma 
and for differential diagnosis from nongerm cell malignancies [9].
Reduced expression of p16 protein due to INK4A promoter methylation is one of the principal 
factors that promote cell proliferation in OMGCTs. Thus, p16 may be a novel target for gene 
therapies to treat OMGCTs [10].
Increased and prolonged expression of stem cell-related proteins (OCT3/4, KIT, and NANOG) 
in the gonadal tissues of trisomy 21 patients suggests that a delay in fetal germ cell differentia-
tion is a key factor in the development of GCTs [11].
Each of the histological subtype of germ cell cancers show recurrent molecular characteristics 
of ploidy indices, DNA copy number changes, and specific expression patterns of mRNA, 
miRNA, and proteins [12].
A familial predisposition has been observed by some with more than one family member or 
sibling affected. Screening of family members is debatable; however, a discussion regarding 
these reports with the affected family may be worthwhile [13].
5. Staging of ovarian tumors
Staging of germ cell tumors is as for other ovarian tumors. The FIGO 2014 staging is given in 
Table 1 [14].
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6. Germ cell tumors in pregnancy
The incidence of ovarian cancer in pregnancy is quite low, 1 in 12,500–25,000 pregnancies. 
The estimated incidence of ovarian tumors is approximately 1 in 1000 pregnancies of which 
approximately 3–6% are malignant [15, 16]. However, a higher incidence of 1 in 143 to 1 in 556 
of ovarian tumors in pregnancy has been reported [17, 18]. The incidence of ovarian tumor in 
pregnant woman requiring surgery was 1 in 1693 (0.025%) [19].
These tumors are relatively asymptomatic; however, the routine use of USG has led to more 
frequent finding of adnexal masses making diagnosis and management more challenging.
Pregnancy associated with ovarian malignancies present significant challenges and need balanc-
ing between optimal maternal therapy and fetal well-being. In addition, cancer diagnosis may 
be delayed because of difficulties in distinguishing symptomatology from physiologic changes 
in pregnancy and the difficulty in applying the standard diagnostic work-up in a pregnant 
Stage Tumor involvement
I Confined to ovaries
IA Confined to 1 ovary without capsular/surface involvement, cytology from peritoneal washings or ascitis −ve
IB Confined to both ovaries without capsular/surface involvement, cytology from peritoneal washings or 
ascitis −ve
IC Confined to 1or both ovary with capsular/surface involvement, cytology from peritoneal washings or ascitis +ve
II Extends beyond ovaries but limited to pelvis
IIA Extension/implants to uterus/tubes, cytology from peritoneal washings or ascitis −ve
IIB Extension to other pelvic tissues, cytology from peritoneal washings or ascitis −ve
III Involves one or both ovaries/fallopian tubes/primary peritoneal cancer, with cytologically or histologically 
confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes
IIIA Metastasis to the retroperitoneal LN with or without microscopic peritoneal involvement beyond the pelvis
IIIA1 Positive retroperitoneal lymph nodes only (cytologically or histologically proven)
IIIA2 Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive 
retroperitoneal lymph nodes
IIIB Macroscopic peritoneal metastases beyond the pelvic brim ≤2 cm in greatest dimension, with or without 
metastasis to the retroperitoneal LN
IIIC Macroscopic peritoneal metastases beyond the pelvic brim >2 cm in greatest dimension, with or without 
metastases to the retroperitoneal LN. 1. Includes extension of tumor to capsule of liver and spleen without 
parenchymal involvement of either organ.
IV Distant metastases
IVA Pleural effusion with positive cytology
IVB Metastases to extra-abdominal organs (including inguinal LN and LN outside abdominal cavity); 
parenchymal metastases of liver and spleen.
Table 1. FIGO 2014 staging.
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woman. Finally, the lack of prospective randomized treatment studies, and therefore, objective 
data has prevented the development of clinical guidelines for most of the issues complicating 
the treatment of pregnancy associated ovarian cancer.
6.1. Clinical features
These tumors may be asymptomatic, diagnosed as adnexal mass during routine antenatal 
ultrasound imaging. The overall estimated incidence of adnexal masses in pregnancy ranges 
from 2 to 10% [20]. With the use of ultrasound in the first trimester, the reported incidence of 
adnexal masses has increased. The incidence gradually decreases due to spontaneous resolu-
tion of many of these masses as gestation advances. These tumors may present with pain, mass 
or distension of abdomen, urinary or bowel symptoms. It can be misdiagnosed as fibroid [21]. 
It can present with acute abdomen, misdiagnosed as acute appendicitis or ectopic pregnancy 
or with bleeding per vaginum [22]. It is difficult to diagnose ovarian malignancies from func-
tional cysts or benign ovarian tumors. The differentials of such an adnexal mass in pregnancy 
include ectopic pregnancy, corpus luteal cyst, functional cyst, paraovarian cyst, endometrioma, 
leiomyoma, and ovarian neoplasms.
6.1.1. Tumor markers in germ cell tumors
The important markers of germ cell tumors are serum alpha feto protein (AFP), human chori-
onic gonadotropin (hCG), and lactic dehydrogenase (LDH).
Alpha-fetoprotein—it is a normal fetal serum protein synthesized by the liver, yolk sac, and 
gastrointestinal tract. Almost all endodermal sinus tumors of the ovary express AFP. AFP is 
also expressed by immature teratomas, ovarian embryonal cell carcinoma, and polyembryo-
mas. It is present in the cytoplasm of tumor cells and in the characteristic hyaline globules 
observed in the endodermal sinus tumor. It is raised in 85% of patients with these tumors but 
in only 20% of patients with stage I disease. Hence, this marker has limited role in screening. 
Typical values seen in normal pregnancy for AFP is 1000 to 10,000 ng/mL, >9 multiples of 
median [23].
AFP is present in 100% women with yolk sac tumor, 61.9% in immature teratoma, and 11.8% 
in dysgerminoma, but no positive case for AFP in mature cystic teratoma and mature cystic 
teratoma with malignant transformation is seen [24].
Pregnancy normal and abnormal, hepatocellular carcinoma, cirrhosis, and hepatitis also may 
be associated with increased levels of serum AFP. Nevertheless, an extremely raised AFP in a 
normal pregnancy may be associated with endodermal sinus tumor, an aggressive malignant 
germ cell tumor.
Human chorionic gonadotropin—it is a glycoprotein produced by syncytiotrophoblast and is 
made of alpha and beta subunits. Choriocarcinoma gestational and nongestational (ovarian) 
both express hCG.
LDH-dysgerminomas are commonly associated with elevations in LDH, although it is not 
elevated in all dysgerminomas. Occasionally, dysgerminomas may become infiltrated with 
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syncytiotrophoblastic giant cells, which produce beta-hCG. Elevations in AFP are less com-
mon with dysgerminomas. Many scientists contend that AFP/hCG secreting dysgerminomas 
are misdiagnosed as pure lesions, and that they actually represent mixed tumors containing 
other malignant germ cell components.
Mixed lesions may secrete AFP, hCG, or both or neither of these markers, depending on the 
components.
Therefore, useful tumor markers for the workup of germ cell tumors include-hCG, AFP, LDH, Inhibin 
A and B to rule out sex cord stromal tumors, Cancer antigen 125 (CA-125) to rule out epithelial tumors.
These serologic elevations of tumor markers readily resolve following surgical excision; and 
may be used as tumor markers to monitor for recurrence.
6.1.2. Limitation of tumor markers in pregnancy
Some established tumor markers are synthesized and secreted physiologically during fetal devel-
opment, i.e., hCG, AFP, inhibin, making them less useful during pregnancy [20]. CA125 increases 
in early pregnancy and post-partum period having limited diagnostic utility. HCG also peaks dur-
ing the first trimester. The values of tumor markers therefore, should be interpreted with caution 
during pregnancy and treatment strategies should not be based on levels of these markers alone.
6.2. Imaging
6.2.1. Imaging in malignant and benign tumors
There are numerous ultrasound features of adnexal masses that have been associated with 
increased risk of malignancy including size, solid components or heterogeneous/complex 
appearance, excrescences/papillary structures, internal septations, bilaterality, irregular bor-
ders, increased vascularity, low resistance blood flow, and presence of ascites [20]. Finding of 
ascites by ultrasound may be closely related with advanced stage malignancy and bad prog-
nosis [25]. Some germ cell tumors have characteristic imaging features, i.e., dysgerminoma, 
mature, and immature teratomas can be diagnosed with high accuracy.
MRI may provide additional information. CT is not recommended in pregnancy due to ion-
ization risk to the developing fetus.
6.2.2. Imaging in torsion of tumors
Sonographically ovarian torsion is demonstrated by visualizing an enlarged, edematous ovary 
along with a mass or cyst. Doppler imaging may fail to demonstrate arterial and/or venous 
blood flow to the ovary. Ovarian torsion is a clinical diagnosis and ultrasound should only 
be used to provide additional supportive diagnostic information. A recent study showed that 
19% of patients with torsion had normal preoperative Doppler flow to the affected adnexa 
[26]. The risk of torsion among pregnant patients with adnexal tumors >4 cm increases, 
51% of torsions occurred in tumors measuring 6–8 cm in diameter. The highest rate of tor-
sion occurred between 15 and 16 weeks of gestation. Sixty percent of the torsion happened 
between the 10th and 17th weeks of gestation [27].
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6.3. Effect of pregnancy on ovarian tumor
Increased risk of torsion, incarceration, rupture, and hemorrhage can occur during pregnancy 
and vaginal delivery.
6.4. Effect of ovarian tumors on pregnancy
Spontaneous successful pregnancy with no feto-maternal compromise has been reported [21]. 
Fetal demise has been reported to be in 25% of cases [28].
6.5. Management in pregnancy
Majority of adnexal masses in pregnancy are benign and a good percentage will spontane-
ously resolve. About 55% of masses resolve completely or significantly decrease in size 
[29, 30]. Best predictors of persistence are complex appearance and size greater than 5 cm.
Observation: Patients with simple or functional appearing small adnexal masses should have 
surveillance with ultrasound every trimester [30, 31].
Surgery: Surgical intervention is required in situations: if malignancy is suspected; if an acute 
complication, i.e., torsion or rupture develops; if any suspicious mass (complex cyst with 
solid components or thick septa) more than 5 cm in size persists near 18 weeks, demonstrates 
a 30–50% increase in size at any time during the pregnancy or exceeds 8 cm in size.
The goals of surgery include: removal of the mass to avoid complications during pregnancy, 
obtain a diagnosis, and to stage or debulk ovarian cancer if malignancy is identified. Laparotomy 
for an adnexal mass is done by a midline incision and begins with obtaining peritoneal washings 
and a complete exploration of the abdomen and contralateral ovary. Manipulation of the uterus 
should be minimized, as this could increase the risk of placental abruption, premature labor, 
or fetal loss. If the clinical suspicion for malignancy is low and it seems technically feasible, a 
cystectomy rather than salpingo-oophorectomy is performed. If, however, the clinical suspicion 
for cancer is high (excrescences, ascites, etc.) or the mass is solid, the tube and ovary should be 
removed. In either case, a frozen section should be obtained.
If a malignancy is confirmed and seems to be confined to the ovary, then a full staging surgery 
including peritoneal biopsies, omentectomy, and lymphadenectomy should be considered; 
however, the benefit gained from the more extensive surgery must be balanced against poten-
tial feto-maternal morbidity. Conservative surgical management for most malignant ovarian 
germ cell tumors diagnosed during pregnancy should be considered as the proper initial 
treatment [32]. Staging is critical as adjuvant therapy during pregnancy, is only initiated for 
those with advanced-stage disease. Routine biopsy or wedge-resection of the contralateral 
ovary is not necessary unless it seems to be involved with disease.
If metastatic disease is detected, an attempt at cytoreduction should be undertaken. The feto-
maternal risk of an extended and radical debulking should be weighed with the potential mater-
nal benefit, realizing that interval cytoreduction after chemotherapy and completion of the 
pregnancy is a reasonable approach [33]. However, the majority of ovarian cancers associated 
with pregnancy are diagnosed at an early stage, when disease is still confined to the ovary [34, 35].
Germ Cell Tumors and their Association with Pregnancy
http://dx.doi.org/10.5772/intechopen.72556
129
In recent years, laparoscopy has been used to manage benign looking adnexal masses with 
minimal morbidity.
6.6. Timing of intervention
The ideal time for intervention is 14–22 weeks gestational age. It avoids the period of greatest 
risk of drug-induced teratogenicity; spontaneous fetal losses due to intrinsic fetal abnormali-
ties have already occurred; the function of corpus luteum has been replaced by the placenta; 
most functional cysts have disappeared; an acceptable operative field is still available, allow-
ing minimal uterine manipulation and low risk of obstetric complications. A later surgery in 
pregnancy, at the end of second trimester or at third trimester, may be technically more dif-
ficult and may result in an adverse obstetric outcome [36].
When indicated for other reasons, cesarean section may also be an opportunity for the surgical 
management of adnexal masses. In patients who undergo vaginal delivery, and in whom surgery 
was not indicated antenatally, a repeat imaging should be performed 6–8 weeks post-partum [37].
6.7. Pregnancy outcome after surgical intervention during pregnancy
Surgery is considered safe in second trimester [38] before 23 weeks, yet the decision to pro-
ceed with surgical management should outweigh the risks of adverse perinatal outcomes. The 
incidences of congenital malformations and stillbirths were not increased in the offspring of 
women having surgery. The incidences of abortions; very-low and low birth weight infants 
were increased due to increase in the risk of prematurity and intrauterine growth retardation. 
[39]. The incidence of infants dying within 168 h was increased. No specific types of anesthe-
sia or operation were associated with adverse outcomes [40].
6.8. Oncologic outcome after surgical intervention in pregnancy
Majority of women at the time of diagnosis of ovarian tumors during pregnancy, have favor-
able results as most have low grade and early stage disease. It is appropriate to consider 
fertility sparing surgery in these young women. However, there are reports about the rapid 
growth and recurrence of ovarian germ cell tumors during pregnancy [28]. Hence, patients 
should undergo comprehensive surgical staging at the time of diagnosis.
6.9. Adjuvant therapy
Germ cell tumors are quite sensitive to chemo and radiotherapy. Chemotherapy usually is 
the adjuvant of choice to spare fertility. BEP (bleomycin, cisplatin, etoposide) is the standard 
adjuvant chemotherapy for 3–4 cycles [41]. Recommendations for chemotherapy are:
• Recurrence during observation (for stage IA dysgerminoma and stage IA grade 1 immature 
teratoma).
• Stage II–IV dysgerminoma.
• Stage II–IV teratoma or stage I grade 2–3.
• Embryonal or endodermal sinus tumor irrespective of stage [42].
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6.9.1. Chemotherapy
Chemotherapy should not be given during the first trimester due to high risk of fetal malfor-
mations. Fetal congenital malformation risk is 10% for single agent and 25% for combination 
chemotherapy in first trimester.
Bleomycin—it is a copper-chelating glycoprotein capable of inducing DNA strand scission 
breaks via oxidative processes. This drug is eliminated by the kidneys. Pulmonary function 
tests are recommended if bleomycin is considered.
Cisplatin—it inhibits DNA synthesis and, thus, cell proliferation, by causing DNA cross-links 
and denaturation of the double helix. Cisplatin is excreted by kidneys; those with impaired 
renal function should postpone therapy.
Carboplatin—carboplatin is an analog of cisplatin. Carboplatin has the same efficacy as cis-
platin but with a better toxicity profile. Its main advantages over cisplatin include less nephro-
toxicity and ototoxicity not requiring extensive pre-hydration and less likelihood of inducing 
nausea and vomiting, but it is more likely to induce myelotoxicity.
Etoposide—etoposide inhibits topoisomerase II and causes DNA strand breakage, causing 
cell proliferation to arrest in the late S or early G2 portion of the cell cycle.
BEP therapy: bleomycin 30 units/week IV on days 1, 8, and 15 plus etoposide 100 mg/m2/day 
IV and cisplatin 20 mg/m2/day IV on days 1 to 5. BEP is given every 21 days for three cycles 
(or four cycles if the patient had bulky residual disease after surgery).
In women with recurrence, confirmed residual disease, or raised tumor markers after first-
line chemotherapy, recommended treatment consists of paclitaxel-ifosfamide-cisplatin (TIP) 
or another acceptable regimen. TIP is given as follows: paclitaxel 250 mg/m2 IV infused over 
24 h on day 1 plus ifosfamide 1500 mg/m2/day IV and cisplatin 25 mg/m2/day IV on days 2 to 6. 
TIP is given every 21 days for four cycles [42].
6.9.1.1. Complications of chemotherapy
The most common medical complications from chemotherapy are bone marrow abnormali-
ties and renal toxicity. Care should be taken to monitor for signs of pulmonary toxicity in 
patients receiving bleomycin-containing regimens. Secondary malignancies are rare, but 
leukemias may occur in patients receiving etoposide, especially if doses exceed 2000 mg/m2  
(i.e., >4 cycles of standard BEP (bleomycin, etoposide, platinum) regimen. BEP treatment has 
been associated with ventriculomegaly, transient neonatal neutropenia and bilateral sensori-
neural hearing loss in few cases [43].
6.9.2. Radiation
Loss of fertility is a problem with radiation. Primary therapy with radiation is reserved for 
patients who are incapable of tolerating chemotherapy or surgical resection. It can be used 
in stage IB to stage III. Radiation is mostly used to treat periaortic and pelvic lymph node 
metastases [44].
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6.10. Follow up
Recurrence of dysgerminomas is most often seen in the first 2–3 years after treatment. 
Therefore, follow-up observation and a physical examination every 3–4 months for the first 
3 years, every 6 months during the fourth and fifth years, and annual surveillance thereafter 
is recommended [44].
CT imaging should be considered during months 6 and 12, especially if tumor markers were 
negative at the time of diagnosis [44].
Patients should be observed for up to 10 years, for late recurrences, although they are rare.
6.11. Prognosis
• The prognosis of OGCT is excellent, as most cases are benign. When malignant they are 
very aggressive, but the prognosis is still good provided it is treated without delay with 
combination chemotherapy [8].
• Most patients with mature teratomas show long survival times.
• The prognosis of immature teratomas is governed by grade and stage. Stage 1, grade 1 have 
100% survival rate, whereas stage III, grade 1 have only a 50% chance of survival.
• The survival rates for dysgerminomas presenting at early and advanced stages are 95 and 
>80%, respectively. In dysgerminoma stage 1a tumor after unilateral salpingo-oophorecto-
my as a fertility preserving surgery has a relapse rate ranging from 10 to 20%; the overall 
survival rate is 90–100% [45]. Patients who suffer relapses and undergo chemotherapy; the 
survival rate for such patients is greater than 90%.
• Endodermal sinus tumors of the ovary are particularly aggressive. The survival rates for 
stage I and II ESTs are reported to be 60–100%, whereas for those with stage III or IV disease 
the prognosis is less favorable (50–75%).
• Survival rates for embryonal carcinoma are slightly higher than those for ESTs.
• Prognosis is better for gestational choriocarcinoma than nongestational carcinoma.
• For mixed GCT, size and histology are the major factors determining prognosis for patients. 
Prognosis is poor for patients with large tumors when more than one-third of the tumor is 
composed of endodermal sinus elements, grade 3 immature teratoma or choriocarcinoma. 
When the tumor is smaller than 10 cm in diameter, the prognosis is good regardless of the 
composition of the tumor [46].
• Data from the Surveillance, Epidemiology and End Results program (1978–2010), investigators 
found a 97%, 5-year cause specific survival in those with ovarian dysgerminoma compared 
with a 92% for those with nondysgerminoma. Significant prognostic factors included age older 
than 40 years at diagnosis and metastatic disease. A second cancer occurred in 10% of all pa-
tients who survived 10 years and had received radiotherapy compared to 2% of those who had 
not received radiation treatment [47].
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7. Dysgerminoma
The most commonly occurring malignant GCT is dysgerminoma, which accounts for approx-
imately 2% of all ovarian cancers. It is the most common ovarian germ cell tumor coexisting 
with pregnancy, and constitutes 25–35% of all reported ovarian cancers. Mostly, it is diag-
nosed at an early stage, when disease is still confined to the ovary.
7.1. Etiology
The exact etiology of dysgerminomas is not identified, though recent molecular studies have 
implicated loss of function with potential tumor suppressor gene TRC8/RNF139 as a possible 
etiology [48]. Cytogenetics reveals 12p abnormalities in 81% of cases [9].
7.2. Pathology
Dysgerminomas are mostly unilateral (15% of dysgerminomas are bilateral), solid, nodular. 
They have a smooth, bosselated (knobby) external surface, is soft, fleshy, either cream-col-
ored, gray, pink or tan when cut. Hemorrhage and necrosis is common, but less prominent 
than other malignant tumors.
Histological examination of dysgerminomas show a proliferation of epithelioid cells admixed 
with mature lymphocytes arranged in sheets or small clusters which are separated by thin, 
fibrous septae resembling alveoli. The neoplastic cells are large and have moderate to high 
nucleus-to-cytoplasm ratios. Other features are round nuclei; vesicular chromatin; prominent 
nucleoli; clear to eosinophilic cytoplasm rich in glycogen and lipid; and distinct cell borders 
(Figure 1) [49].
Multinucleated forms may be present. Mitotic activity may be significant and may vary 
greatly, even within the same tumor; atypical mitoses may be seen. Noncaseating granulo-
mas, syncytiotrophoblast-like giant cells and germinal center formation are not uncommon. 
Additionally, foci of hemorrhage, necrosis, and small microcalcifications may also be identi-
fied [49, 50].
The neoplastic cells of dysgerminomas express placental alkaline phosphatase (PLAP), 
CD117 (c-kit), OCT 3/4, SALL4, and, variably, cytokeratin [49]. Positive stain for OCT4 (strong 
nuclear staining) in 90%+ cells is seen.
They do not express epithelial membrane antigen (EMA), S100 protein, CD45 (LCA), or alpha-
fetoprotein (AFP) [49]. Syncytiotrophoblast-like giant cells are the source of beta-hCG pro-
duction. A negative stain for CK7, CK20, HMW keratin, CD30 and vimentin is also found [51].
7.3. Imaging in dysgerminomas
In dysgerminoma, characteristic imaging findings include multilobulated solid masses 
with prominent fibrovascular septa. The anechoic, low-signal-intensity, or low-attenuation 
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area of the tumor represents necrosis and hemorrhage. Lobules are richly vascularized at 
color/power Doppler examination which show prominent arterial flow within the fibro 
vascular septa with a resistive index value ranging from 0.44 to 0.70 [52]. On MRI, dysger-
minomas are often seen divided into lobules by septa. Reported signal characteristics are 
hypointense or isointense septae on T2 weighted images. In T1 C+ (Gd) weighted images, 
the septae often show marked enhancement.
8. Teratoma
They represent 20% of all ovarian tumors, 75%, occur in first two decades of life, 12–15% are 
bilateral and 60–70% are diagnosed in stage 1.
Teratomas range from benign, well-differentiated (mature) cystic lesions to those that are solid 
and malignant (immature). Additionally, teratomas may be monodermal and highly special-
ized (struma ovarii, carcinoid). Rarely, in some mature teratomas containing certain elements 
(most commonly squamous components) undergo malignant transformation.
8.1. Mature cystic teratoma
Ovarian mature cystic teratomas, also called dermoid cysts, are the most common germ cell 
tumor, accounting for up to 70% of benign ovarian masses in the reproductive years and 20% 
in postmenopausal women [53, 54]. They maintain rather orderly arrangements, with well-
differentiated ectodermal and mesodermal tissues surrounding endodermal components, 
resembling any tissue of the body. Examples include hair, teeth, fat, skin, muscle, and endo-
crine tissue (Figure 2).
Figure 1. Dysgerminoma: Microsection showing tumor cells with vesicular nuclei.  Fibrous septa showing lymphocytic 
infiltrate (400×, H&E stain). (With permission from [21]).
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Monodermal teratoma comprise of mainly one tissue element. For example, the most com-
mon type of monodermal teratoma, Struma ovarii, is comprised of at least 50% mature thy-
roid tissue (Figures 3 and 4). Argentaffin cells in dermoid cysts are usually the site of origin 
for ovarian carcinoid tumor, although this is rare (Figure 5).
Tumor markers-Mature teratomas rarely produce alpha feto protein and CA125.Elevated AFP 
and HCG levels may be indicative of malignancy.
8.1.1. Imaging
In mature cystic teratoma, transvaginal ultrasound scan (TVS) has 85–98% accuracy [55, 56]. 
Sonographic features includes: diffusely or partially echogenic mass with posterior sound 
attenuation owing to sebaceous material and hair within the cyst cavity, an echogenic 
interface at the edge of mass that obscures deep structures: the tip of the iceberg sign, mural 
hyperechoic Rokitansky nodule: dermoid plug, echogenic shadowing, calcific or dental 
Figure 2. Dermoid cyst: cut section of dermoid cyst of ovary showing hairs and pultaceous material.
Figure 3. Struma ovarii: cut section of ovary containing pultaceous material along with gray white nodule measuring 
2.5 × 2 cm.
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(tooth) components, the presence of fluid levels, multiple thin echogenic bands caused by 
the hair in the cyst cavity: the dot-dash pattern. In color Doppler, no internal vascularity is 
seen [57].
Further workup is required if internal vascularity is found to exclude a malignant lesion. 
When ruptured, the characteristic hypoattenuating fatty fluid can be found in antidependant 
pockets, typically below the right hemidiaphragm, a pathognomonic finding [58].
Figure 5. Carcinoid tumor: cells arranged in parallel ribbon like manner. Nuclei have characteristic salt and pepper like 
chromatin (40× H&E).
Figure 4. Struma ovarii: microsection showing thyroid tubules containing colloid in lower part of image. Upper part 
shows carcinoid element in which tumor cells are arranged in nests (4× H&E).
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MR imaging is reported to have 99% accuracy. The sebaceous component of dermoid cysts 
has very high signal intensity on T1-weighted images similar to that of retroperitoneal fat. 
The signal intensity of the sebaceous component on T2-weighted images is variable, usually 
near that of fat [59].
8.1.2. Histology
Cyst cavity is often lined with keratinized squamous epithelium and usually contains abundant 
sebaceous and sweat glands (Figure 6). There is usually a raised protuberance projecting into the 
cyst cavity known as the Rokitansky nodule. Most of the hair typically arises from this protuber-
ance. When bone or teeth are present, they tend to be located within this nodule. Occasionally, 
the cyst wall is lined with bronchial or gastrointestinal epithelium. Foreign body giant cell reac-
tions may be seen in various parts of the tumor and may, in the case of intraperitoneal tera-
tomas, lead to formation of extensive adhesions if the tumor contents are spilled. Ectodermal 
tissue may include brain, glia, neural tissue, retina, choroids, and ganglia. Mesodermal tissue is 
represented by bone, cartilage, smooth muscle, and fibrous tissue (Figure 7) [60].
8.1.3. Complications in teratoma
Torsion is the most significant cause of morbidity, occurring in 3–11% of cases [61, 62]. Rupture 
may occur suddenly in 2.5% [63] leading to shock or hemorrhage with acute chemical perito-
nitis. Chronic leakage also may occur, with resultant granulomatous peritonitis. Infection is 
uncommon and occurs in less than 1–2% of cases [63].
Malignant transformation: seen in 1–2%, usually into squamous cell carcinoma [64, 65].
Figure 6. Mature cystic teratoma: microsection showing cystic lining with underlying sebaceous glands (40× H&E).
Germ Cell Tumors and their Association with Pregnancy
http://dx.doi.org/10.5772/intechopen.72556
137
In less than 1% autoimmune hemolytic anemia has been associated with mature cystic 
teratomas [66, 67]. Recently recognized encephalitis associated with antibodies against the 
N-methyl-D-aspartate receptor (NMDAR) is associated with ovarian mature teratomas. 
Substantial recovery is usually seen with tumor resection and immunotherapy [68].
8.1.4. Treatment
Mature ovarian teratomas are slow growing (1–2 mm a year) and, therefore, some advocate non-
surgical management. Larger lesions are often surgically removed. Many recommend annual fol-
low-up for lesions <7 cm to monitor growth, beyond which resection is advised. Mature cystic 
teratomas of the ovaries may be removed by simple cystectomy rather than salpingo-oophorectomy.
Although malignant degeneration is quite rare, the cyst should be removed in its entirety, and 
if immature elements are found, the patient should undergo a standard staging procedure.
Spillage is associated with increased risk of chemical peritonitis (estimated incidence of 0.2%) 
and increased risk of adhesion formation. The risks of recurrence (4%), as well as malignant 
degeneration (0.2–2%), should be discussed.
8.2. Immature teratoma
Immature cystic teratomas are rare (<3%) and usually occur in the postmenopausal age group 
[69]. Teratomas, specifically solid teratomas, are essentially devoid of organization. Immature 
teratomas account for approximately 20% of all malignant GCT. Immature teratomas are solid 
tumors containing immature or embryonal tissues (Figure 8). It is found either in pure form 
or as a component of a mixed germ cell tumor.
Immature neuroepithelium is the predominant immature tissue found. Grade is based upon 
the proportion of tissue containing immature neural elements and is considered an important 
prognostic factor that predicts extra ovarian spread and overall survival. They are classified as 
Grade I, II, or III if they have 0 or 1, 3 or less, or 4 or more low-power fields (x-40) containing 
immature neuroepithelium per slide, respectively [50].
Figure 7. Dermoid cyst: microsection showing cartilaginous element (10× H&E).
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8.2.1. Imaging
Immature teratomas have prominent solid components and may demonstrate internal necro-
sis or hemorrhage. Mature tissue elements similar to those seen in mature cystic teratoma are 
invariably present. Radiologic examination reveals a large, complex mass with cystic, solid 
components, and scattered calcifications; in contrast, calcification in mature teratomas is local-
ized to mural nodules. Small foci of fat are also seen in immature teratomas. These tumors 
grow rapidly and frequently demonstrate perforation of the capsule. The tumor capsule is not 
always well defined.
8.2.2. Management of immature teratoma
Fertility-sparing surgery should be offered when detected during pregnancy with surgical 
staging. Thus unilateral salpingo-oophorectomy with preservation of contralateral ovary 
with uterus is the appropriate treatment in most cases. If metastatic disease is found dur-
ing surgery, cytoreductive surgery is recommended. Stage 1a/G1 does not require adjunct 
treatment and can be observed. Chemotherapy is recommended when extra-ovarian disease 
exists, stage I grade 2–3. BEP is the most commonly used combination every 3 weeks for 3–4 
courses.
8.2.3. Prognosis
The prognosis of immature teratomas is governed by grade and stage. Cases of grade 1 in 
stage I might have up to a 94% survival rate, whereas cases of grade 2 or 3 in stage I might 
drop to an 82% chance of survival. Grade also contributes to the recurrence rate, with higher 
grades having a higher recurrence rate [70, 71].
Figure 8. Immature teratoma of ovary: Irregular, partially encapsulated, solid tumor measuring 9 × 6 × 4 cm. Cut surface 
is grayish white with areas of hemorrhage and foci of necrosis.
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9. Endodermal sinus tumor or yolk sac tumor
Endodermal sinus tumor (EST), also known as yolk sac tumor, is a rare malignant ovarian 
tumor that usually occurs in the second decade of life. The tumor manifests as a large, complex 
pelvic mass that extends into the abdomen and contains both solid and cystic components. 
The cystic areas are composed of epithelial line cysts produced by the tumor or of co-existing 
mature teratomas. These tumors grow rapidly and have a poor prognosis. Affected patients 
have an elevated serum α-fetoprotein level, alpha 1 antitrypsin.
Gross examination of EST demonstrates smooth, glistening, hemorrhagic, and necrotic sur-
faces. Histology reveals a wide range of patterns (microcystic endodermal sinus, solid, alve-
olar-glandular, papillary, macrocystic, hepatoid, and primitive endodermal). On microscopic 
examination, it contains Schiller-Duval bodies (central capillary surrounded by simple papil-
lae) and eosinophilic globules containing AFP (Figure 9). Intracellular and extracellular hya-
line droplets (periodic acid-Schiff positive) are also seen in EST.
When diagnosed during pregnancy, it is often possible to continue the pregnancy after sur-
gical staging and tumor debulking. For metastatic disease, the principles of cytoreductive 
surgery also apply, and the goal is the resection of all lesions to a minimal residual volume.
10. Non-gestational choriocarcinoma
In reproductive age group, the symptoms could resemble pregnancy with amenorrhoea and 
positive urine pregnancy test. The predominant presenting symptoms are lower abdomi-
nal pain, genital bleeding, amenorrhea, nausea and vomiting because of high levels of 
hCG. Choriocarcinoma is often diagnosed by finding an elevated hCG level in association 
with metastatic lesion detected radiographically. The levels of serum/urine beta hCG are 
good tumor marker for the progression or remission of disease. Paternal contribution pres-
ent in the genome of the tumor is necessary to differentiate gestational from nongestational 
Figure 9. Yolk sac tumor: microsection showing Schiller-Duval bodies (40× H&E).
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tumors. Serum β2 microglobulin may be used as a marker for non-gestational choriocarci-
noma, though the cause of β2 microglobulin expression in non-gestational choriocarcinoma 
is unknown [72].
11. Pure embryonal carcinoma
It is rare in the ovary, may secrete estrogen, with patient exhibiting symptoms and signs of 
precocious puberty or irregular vaginal bleeding. Embryonal cell carcinoma has more nuclear 
hyperchromasia and nuclear pleomorphism, amphophilic cytoplasm, high mitotic index, and 
necrosis. Often, a glandular or papillary architecture is present. The cells of embryonal carci-
noma express CD30 and cytokeratin (strong, diffuse), whereas those of dysgerminoma do not.
12. Mixed germ cell tumors
These are rare germ cell tumors. A mixture of dysgerminoma and endodermal sinus tumor 
is the most common combination accounting for one-third of mixed germ cell tumors [73]. 
Combination of embryonal carcinoma and choriocarcinoma is very rare. The prognosis of 
patients with a mixed MGCT usually reflects that of its most malignant component. Therefore, 
it is important to sample these tumors extensively, particularly areas with different gross 
appearance. One section per every centimeter in tumor diameter is recommended [74].
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